North China Pharmaceutical Company.Ltd Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Xin Yan Liu

İcra Kurulu Başkanı

CN¥262.4k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

Benign Growth For North China Pharmaceutical Company.Ltd (SHSE:600812) Underpins Its Share Price

Sep 25

North China Pharmaceutical Company.Ltd's (SHSE:600812) Profits Appear To Have Quality Issues

Aug 20

The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

Apr 26

CEO

Xin Yan Liu (54 yo)

3.3yrs

Görev süresi

CN¥262,400

Tazminat

Mr. Xin Yan Liu is General Manager and Director of North China Pharmaceutical Company Ltd. since August 13, 2021 and served as its Deputy General Manager.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xin Yan Liu	GM & Director	3.3yrs	CN¥262.40k	Veri yok
Jianjun Li	CFO & Chief Accountant	3.3yrs	CN¥200.40k	Veri yok
Zhi Shan Chang	Deputy GM & Secretary	8.7yrs	CN¥200.40k	Veri yok

3.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 600812 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xin Yan Liu	GM & Director	3.3yrs	CN¥262.40k	Veri yok
Guangcheng Pan	Independent Director	5.5yrs	CN¥71.40k	Veri yok
Xiaohan Liu	Independent Director	5.5yrs	CN¥71.40k	Veri yok
Yao Cao	Director	6.2yrs	CN¥200.40k	Veri yok
Fan Li	Supervisor	6.2yrs	Veri yok	Veri yok
Jigang Xie	Independent Director	3.6yrs	CN¥71.40k	Veri yok
Demin Zhou	Independent Director	5.5yrs	CN¥71.40k	Veri yok
Rentao Song	Director	1.7yrs	Veri yok	Veri yok
Wei Lv	Chairman of the Supervisory Board	2.1yrs	Veri yok	Veri yok
Wenzan Gao	Supervisor	2.1yrs	Veri yok	Veri yok

4.5yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600812 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

North China Pharmaceutical Company.Ltd Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

North China Pharmaceutical Company.Ltd, Annual General Meeting, Jun 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.018 (vs CN¥0.001 in 3Q 2023)

North China Pharmaceutical Company.Ltd to Report Q3, 2024 Results on Oct 26, 2024

Benign Growth For North China Pharmaceutical Company.Ltd (SHSE:600812) Underpins Its Share Price

North China Pharmaceutical Company.Ltd's (SHSE:600812) Profits Appear To Have Quality Issues

Second quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.012 in 2Q 2023)

North China Pharmaceutical Company.Ltd to Report First Half, 2024 Results on Aug 14, 2024

North China Pharmaceutical Company.Ltd, Annual General Meeting, Jun 26, 2024

The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

First quarter 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.003 in 1Q 2023)

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: CN¥0.003 (vs CN¥0.40 loss in FY 2022)

North China Pharmaceutical Company.Ltd to Report Q1, 2024 Results on Apr 26, 2024

Now 21% undervalued after recent price drop

North China Pharmaceutical Company.Ltd to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.003 in 3Q 2022)

North China Pharmaceutical Company.Ltd to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.012 (vs CN¥0.011 in 2Q 2022)

Now 21% undervalued after recent price drop

North China Pharmaceutical Company.Ltd to Report First Half, 2023 Results on Aug 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.003 (vs CN¥0.008 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released

First quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.035 loss in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.028 in 2Q 2020)

First quarter 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.039 profit in 1Q 2020)

New 90-day low: CN¥8.48

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.80

New 90-day low: CN¥10.25

Jizhong Energy Resources Co., Ltd. (SZSE:000937) completed the acquisition of a 10% stake in North China Pharmaceutical Company. Ltd (SHSE:600812) from Jizhong Energy Group Company Limited.

Third quarter earnings released

New 90-day low: CN¥11.53

Third quarter earnings released

North China Pharmaceutical Company. Ltd to Report Q3, 2020 Results on Oct 23, 2020

First half earnings released

New 90-day high - CN¥15.07

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş